NeuroTransData, a German neurology network of 66 outpatient sites has been collecting real world data in a Registry database for MS with more than 23,000 patients for more than 10 years.
Patients and Methods / Material and Methods
RRMS-patients stable on injectable DMDs (Avonex R , Rebif R , Betaferon/Extavia R , Copaxone R ) for 4,3y (median) were analyzed for 6.1y (median) regarding clinical course and potential switch to oral and other treatments.
Results 2682 (41.7%) of these 6427 patients were switched to oral DMD. The other patients stayed on their DMD for 4.6 years (median). The main reasons for switching were insufficient therapeutic effect (34.2%), side effects (18.1%) and patient's wish (18.2%). After 1.1 years (median), 716 (26.7%) of these already switched patients were switched once again to another DMD, 123 (17.2%) switched back to their first DMD. 1735 patients (65%) remained on their first switch therapy. Observation period was 3.8 years (median).
Conclusion
The main reason for switching from injectable to oral DMD was the therapeutic effect, followed by patient's wish and side effects. In those patients who switched a second time, side effects were the main reason for switching. Most patients (65%) who switched from injectable to oral DMDs remained on that therapy during the observation period. 
